Viking Therapeutics company info

What does Viking Therapeutics do?
Viking Therapeutics (NASDAQ:VKTX) is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Their portfolio consists of promising candidates aimed at treating conditions such as hypothyroidism, non-alcoholic fatty liver disease, and muscle wasting. Viking Therapeutics is dedicated to advancing these projects through clinical trials, with the ultimate objective of addressing unmet medical needs and improving patient lives. Through their rigorous research and innovative approach, they strive to develop effective treatments that can lead to better health outcomes for individuals affected by these disorders.
Viking Therapeutics company media
Company Snapshot

Is Viking Therapeutics a public or private company?

key
Ownership
Public

How many people does Viking Therapeutics employ?

people
Employees
26

What sector is Viking Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Viking Therapeutics?

location pin
Head Office
San Diego, United States

What year was Viking Therapeutics founded?

founded flag
Year Founded
2012
What does Viking Therapeutics specialise in?
/Biopharmaceutical Company /Metabolic Disorders /Endocrine Disorders /Drug Development /Clinical Trials /Innovative Medicines

What are the products and/or services of Viking Therapeutics?

Overview of Viking Therapeutics offerings
VK2809 is in development for lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis (NASH).
VK5211, aimed at treating patients recovering from hip fractures by enhancing lean body mass and bone density.
VK0214 targets X-linked adrenoleukodystrophy (X-ALD), a genetic disorder affecting the nervous system and adrenal glands.
VK2735 is being explored for its potential in treating autoimmune diseases, offering a new approach to immune modulation.
Development of a novel class of selective androgen receptor modulators (SARMs) for treating conditions associated with muscle and bone wasting.
Research into thyroid beta agonists, exploring innovative treatments for metabolic and cardiovascular diseases.

Who is in the executive team of Viking Therapeutics?

Viking Therapeutics leadership team
  • Dr. Brian  Lian Ph.D.
    Dr. Brian Lian Ph.D.
    President, CEO & Director
  • Mr. Gregory S. Zante
    Mr. Gregory S. Zante
    Chief Financial Officer
  • Ms. Marianne  Mancini
    Ms. Marianne Mancini
    Chief Operating Officer
  • Mr. Michael  Morneau
    Mr. Michael Morneau
    Vice President of Finance & Administration
  • Dr. Geoffrey E. Barker Ph.D.
    Dr. Geoffrey E. Barker Ph.D.
    Senior Vice President of Pharmaceutical Development